Effects of French maritime pine bark extract (Oligopin®) supplementation on bone remodeling markers in postmenopausal osteopenic women: A randomized clinical trial. (24th March 2019)

• Record Type: Journal Article
• Authors: Panahande, Seyed Bahman; Maghbooli, Zhila; Hossein‐nezhad, Arash; Qorbani, Mostafa; Moeini‐Nodeh, Shermineh; Haghi‐Aminjan, Hamed; Hosseini, Saeed
• Is Part Of: Phytotherapy research. Volume 33:Number 4(2019)
• Page Start: 1233
• Page End: 1240
• Publication Date: 2019-03-24
• Subjects: bone remodeling -- French maritime pine bark extract -- Oligopin -- osteopenic -- postmenopausal; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.6320
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : French maritime pine bark extract (FMPBE; Oligopin®), a dietary supplement, is rich in procyanidin. The objective of this study was to determine the effects of FMPBE on bone remodeling in postmenopausal osteopenic women. This randomized, double‐blinded, placebo‐controlled clinical trial was conducted on 40 postmenopausal osteopenic women. Individuals were randomly assigned to either FMPBE (250 mg/day, n = 21) or placebo (250‐mg starch/day, n = 19) for 12 weeks. Biochemical indices, including bone remodeling marker, were assessed before and after the intervention. After the 12‐week intervention, that is, FMPBE supplementation, a significant increase in bone alkaline phosphatase (BAP), procollagen type 1 amino‐terminal propeptide (P1NP) levels and a significant decrease in C‐terminal telopeptide of type I collagen (CTx1) were observed. Compared with the control group, FMPBE supplementation resulted in a significant increase in P1NP (0.015), BAP levels (0.001), and BAP/CTx1 ratio ( p = 0.001) and a significant decrease in CTx1 levels (0.006). FMPBE supplementation for 12 weeks in postmenopausal osteopenic women produced favorable effects on bone markers. Meanwhile, further research is needed to determine whether FMPBE supplements can be used as a preventive strategy for bone loss in postmenopausal osteopenic women.